Synaptic Plasticity and Cognitive Function in RASopathies
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The project is targeting cognitive impairment, one of the main health problems of patients
with RAS pathway disorders. The aim of this study is to translate findings of animal studies
to humans. This has been done by the applicants successfully for Lovastatin in Nf1. This
result will be transferred to patients with Noonan Syndrome. lamotrigine is most likely a
more effective and promising substance improving synaptic plasticity and consecutive
cognitive function. It is expected that both substances are improving synaptic plasticity as
well as alertness and changes in alertness may be a precondition for improvement of
cognition.
Phase:
Phase 2
Details
Lead Sponsor:
Technische Universität München
Treatments:
Anticonvulsants Dihydromevinolin L 647318 Lamotrigine Lovastatin